FDA "Compassionate Use" Rule Will Outline Access Options Outside Trials
Executive Summary
FDA is developing a rule to describe criteria for a range of ways to offer drug treatment options to patients not participating in clinical trials.
You may also be interested in...
Cancer Expanded Access Plans Need Focus On Data Collection – FDA’s Pazdur
Expanded access programs for cancer products should be limited in scope to gather data on use in patients with refractory disease, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said at the American Society of Clinical Oncology annual meeting in Orlando May 18
Cancer Expanded Access Plans Need Focus On Data Collection – FDA’s Pazdur
Expanded access programs for cancer products should be limited in scope to gather data on use in patients with refractory disease, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said at the American Society of Clinical Oncology annual meeting in Orlando May 18
EU Generic Approvals Could Accelerate By Two Years With Bolar Changes
The European Commission's proposed patent reforms could accelerate the approval of generic drugs by two years.